Abstract
Summary
This report is an essential source for in-depth information and data relating
to the Japan Drug Delivery Devices devices market. It also offers detailed and
comprehensive coverage of market revenue, volume, distribution and company
share information; and latest news, financial deals and pipeline products
information of each of the key sub-segments of the Drug Delivery Devices in
Japan
Scope
・ The report provides drug delivery devices information broken down into
detailed categories and segments in Japan.
・ Total revenues, products
sold, end users, and average pricing.
・ Market shares of all the key
competitors.
・ Key pipeline products that are set to shape the market,
broken down by sector.
・ Information on the top medical equipment
companies in the sector in the country covering business description,
strategic analysis, and financial information.
・ Healthcare structure,
regulatory environment, approval process, pricing trends and
reimbursement.
・ Product and brand updates, strategy changes, R&D
projects, corporate expansions and contractions and regulatory changes.
Key mergers and acquisitions, partnerships, private equity investments and
IPOs.
・ Customer, hospitals and physicians data.
Reasons to
buy
・ Gain a strong understanding of the drug delivery devices market in
Japan.
・ Evaluate and compare the attractiveness of the market in the
country.
・ Identify growth segments and opportunities in each industry
sector within the country.
・ Evaluate the pipeline of key products that
will change the sector, and identify threats and opportunities before the
products are launched in the country.
・ Analyze the competitiveness of the
market in the country and identify hotspots.
・ Develop strategies based
on the latest product, brand, expansion and research and development news in
the country.
・ Do deals with an understanding of how competitors are
financed, and the mergers and partnerships that have shaped the market in the
country.
・ Identify and analyze the strengths and weaknesses of the
industry incumbents in the country.
Table of Contents
1 Table Of Contents
1 Table Of Contents 2
1.1 List of Tables 11
1.2 List of Figures 14
2 Introduction 16
2.1 What Is This Report
About? 16
2.2 Definitions 16
2.2.1 Drug delivery devices 16
3
Healthcare Sector Review 18
3.1 Healthcare Sector Review 18
3.2
Healthcare Expenditure 18
3.3 Healthcare Infrastructure 20
3.4
Healthcare Policy 23
4 Drug Delivery Devices in Japan 24
4.1 Drug
Delivery Devices Overall Revenues (2000-2012) 24
4.2 Drug Delivery Devices
Overall Volume (2000-2012) 30
4.3 Drug Delivery Devices Company Shares
(2005-2006) 33
5 Inhalation Systems in Japan 34
5.1 Inhalation Systems
Overall Revenues (2000-2012) 34
5.1.1 Metered Dose Inhaler Devices Overall
Revenues (2000-2012) 38
5.1.2 Dry Powder Inhaler Devices Overall Revenues
(2000-2012) 40
5.2 Inhalation Systems Overall Volume (2000-2012) 42
5.2.1 Metered Dose Inhaler Devices Overall Volume (2000-2012) 44
5.2.2 Dry
Powder Inhaler Devices Overall Volume (2000-2012) 46
5.3 Inhalation
Systems Average Price (2000-2012) 48
5.3.1 Metered Dose Inhaler Devices
Average Price (2000-2012) 48
5.3.2 Dry Powder Inhaler Devices Average
Price (2000-2012) 50
5.4 Inhalation Systems Distribution Share (2005-2006)
52
5.5 Inhalation Systems Company Share (2005-2006) 53
6 Infusion
Systems in Japan 54
6.1 Infusion Systems Overall Revenues (2000-2012)
54
6.1.1 Infusion Disposable Sets Overall Revenue (2000-2012) 58
6.1.2
Syringe Pumps Overall Revenue (2000-2012) 60
6.1.3 Infusion Pumps Overall
Revenues (2000-2012) 62
6.2 Infusion Systems Overall Volume (2000-2012)
64
6.2.1 Infusion Disposable Sets Overall Volume (2000-2012) 65
6.2.2
Syringe Pumps Overall Volume (2000-2012) 67
6.2.3 Infusion Pumps Overall
Volume (2000-2012) 69
6.3 Infusion Systems Average Price (2000-2012)
71
6.3.1 Infusion Pumps Average Price (2000-2012) 71
6.3.2 Syringe
Pumps Average Price (2000-2012) 73
6.3.3 Infusion Disposable Sets Average
Price (2000-2012) 75
6.4 Infusion Systems Distribution Share (2005-2006)
77
6.5 Infusion Systems Company Share (2005-2006) 78
7 Needle Free
Injections in Japan 79
7.1 Needle Free Injections Overall Revenue
(2000-2012) 79
7.2 Needle Free Injections Overall Volume (2000-2012)
81
7.3 Needle Free Injections Average Price (2000-2012) 83
7.4 Needle
Free Injections Distribution Share (2005-2006) 85
7.5 Needle Free
Injections Company Share (2005-2006) 86
8 AstraZeneca PLC Company Profile
87
8.1 Company Overview 87
8.2 Business Overview 87
8.2.1 Products
89
8.2.2 History 90
8.3 Locations And Subsidiaries 91
8.4
Financial Deals Landscape 93
8.4.1 AstraZeneca Completes $6,900 Million
Private Placement 93
8.4.2 AstraZeneca Acquires MedImmune 94
8.4.3
AstraZeneca Acquires Biologics Manufacturing Facility From DSM Biologics
96
8.4.4 AstraZeneca Acquires Arrow Therapeutics 97
8.4.5 AstraZeneca
Signs An Agreement With Palatin Technologies 99
8.4.6 AstraZeneca Signs An
Agreement With Bristol-Myers Squibb 100
8.4.7 AstraZeneca Signs An
Agreement With Cubist Pharmaceuticals 102
8.4.8 AstraZeneca Signs An
Agreement With Par Pharmaceutical 103
8.4.9 Schering Signs An Agreement
With AstraZeneca 104
8.4.10 AstraZeneca Signs An Agreement With Pozen
106
8.4.11 AstraZeneca Signs An Agreement With Abbott 107
8.4.12
AstraZeneca To Sell Its U.S Anaesthetic and Analgesic Product Portfolio To
Abraxis BioScience 109
8.4.13 AstraZeneca Acquires KuDOS Pharmaceuticals
110
8.4.14 AstraZeneca Acquires A Stake In Protherics 112
8.4.15
AstraZeneca Signs An Agreement With Targacept 113
8.4.16 AstraZeneca Signs
An Agreement With AtheroGenics 115
8.4.17 AstraZeneca UK Signs An
Agreement With Protherics 117
8.4.18 AstraZeneca Signs An Agreement With
Bayer Schering Pharma Aktiengesellschaft 118
8.4.19 AstraZeneca Signs An
Agreement With Astex Therapeutics 120
8.4.20 AstraZeneca Signs An
Agreement With Avanir Pharmaceuticals 121
8.4.21 AstraZeneca And Royal
Cosun Sells Joint Venture Advanta To Syngenta 123
8.4.22 AstraZeneca
Completes Private Placement Of $750 million 125
8.4.23 AstraZeneca Prices
EUR750 Million Private Placement 126
8.4.24 AstraZeneca Prices Sterling
Bond GBP350 Million And Euro750 Million Eurobond Private Placement 127
8.5 Recent Developments 129
8.5.1 Feb 22, 2008: AstraZeneca To Appeal
Judgment In Alabama Medical Pricing Case 129
8.5.2 Feb 18, 2008:
AstraZeneca Appoints Non-Executive Director 129
8.5.3 Dec 12, 2007:
AstraZeneca Files Patent Infringement Actions in Response to Crestor ANDAs
129
8.5.4 Sep 28, 2007: AstraZeneca Appoints New CFO 130
8.5.5 Jul 25,
2007: AstraZeneca Appoints New Board Member 131
8.5.6 Jun 06, 2007:
AstraZeneca CFO Resigns 131
8.5.7 Feb 22, 2007: AstraZeneca To Invest $120
Miilion For R&D In Macclesfield Site 131
8.5.8 Jan 30, 2007: Philips And
Leading Healthcare Companies Join For Major Research And Development 132
8.5.9 Jan 22, 2007: AstraZeneca Makes $100 Million Research Investment In
Boston 132
9 3M Company Profile 134
9.1 Company Overview 134
9.2
Business Overview 134
9.2.1 Consumer and Office 134
9.2.2 Display and
Graphics 135
9.2.3 Electro and Communications 135
9.2.4 Health Care
136
9.2.5 Industrial and Transportation 137
9.2.6 Safety, Security and
Protection Services 137
9.2.7 Products 138
9.3 Value Chain Analysis
140
9.3.1 Manufacturing 140
9.3.2 Product Development 140
9.3.3
Sales and Marketing 141
9.4 SWOT Analysis 143
9.4.1 3M Company
Strengths 143
3M Company Weaknesses 144
3M Company Opportunities
144
3M Company Threats 145
9.5 Revenue Analysis 146
9.5.1 Revenue
by Segment 146
9.5.2 Revenue by Geography 147
9.6 Financial and
Operational Review 149
9.6.1 Financial Statements 149
9.6.2 Financial
Ratios 150
9.7 Locations And Subsidiaries 151
9.8 Financial Deals
Landscape 152
9.8.1 3M Canada Acquires Les Entreprises Solumed 152
9.8.2 3M Acquires Bondo 153
9.8.3 3M Acquires Lingualcare 155
9.8.4 3M
Acquires Abzil Industria E Comercio 157
9.8.5 3M Acquires Neo Plast
159
9.8.6 3M Acquires Assets Of DMS Chile 161
9.8.7 3M Acquires
Business Of Innovative Paper Technologies 163
9.8.8 3M Acquires Powell
165
9.8.9 Gen-Probe Signs An Agreement With 3M Company 167
9.8.10 3M
Acquires Acolyte Biomedica 169
9.8.11 3M Acquires Sealed Air Corp.' S
Interest In Polymask Corp. 171
9.8.12 3M Sells Its Pharmaceutical Business
To Meda AB 173
9.8.13 3M Acquires SoftMed Systems 175
9.8.14 3M Sells
its Pharmaceuticals Business to Graceway 177
9.8.15 Gen-Probe Signs An
Agreement With 3M 179
9.8.16 3M Sells its Pharmaceutical Operations in the
Asia Pacific Region to Ironbridge Capital and Archer Capital 181
9.8.17 3M
Acquires Biotrace International 183
9.8.18 Ekahau Secures $16 Million In
Additional Funding 185
9.8.19 3M Acquires Brontes Technologies 188
9.8.20 3M acquires Nylonge Corp 190
9.8.21 3M Signs An Agreement With
ClozeX Medical 192
9.8.22 3M Acquires OMNII Oral Pharmaceuticals 193
9.8.23 3M Sells Pharmaceutical Operations In The United States To Graceway
195
9.8.24 3M Sells Pharmaceutical Business In Europe To Meda AB 198
9.8.25 3M Sells Pharmaceutical Operations In The Asia Pacific To Ironbridge
and Archer Capital 200
9.8.26 3M Acquires Accuspray Application
Technologies Inc. 203
9.8.27 3M to acquire Rochford Thompson Equipment
205
9.8.28 3M To Acquire Aearo Technologies From Permira 207
9.8.29
Permira To Sell Aearo Technologies To 3M 209
9.9 Recent Developments
212
9.9.1 Mar 31, 2008: HighJump Software Introduces Survey Management
Solution for Direct Store Delivery Businesses 212
9.9.2 Mar 24, 2008:
Brazil' s Companhia de Transmissao de Energia Eletrica Paulista Chooses 3M ACCR
for Upgrade of Line Over Parana River in Sao Paulo State 212
9.9.3 Mar 19,
2008: 3M to Headquarter Optical Systems Business in Asia 214
9.9.4 Mar 19,
2008: 3M To Headquarter Optical Systems Business In North Asia 214
9.9.5
Feb 11, 2008: 3M Increases Dividend for the 50th Straight Year 214
9.9.6
Nov 12, 2007: 3M Declares Quarterly Dividend 214
9.9.7 Oct 24, 2007: 3M
And Sanyo Settle Suit On Lithium Ion Battery 214
9.9.8 Aug 13, 2007: 3M
Declares Quarterly Dividend 215
9.9.9 May 08, 2007: 3M Declares Quarterly
Dividend 215
9.9.10 Apr 30, 2007: Gen-Probe And 3M Collaborate To Develop
Rapid Molecular Tests 215
10 Baxter International Company Profile 216
10.1 Company Overview 216
10.2 Business Overview 216
10.2.1 BioScience
216
10.2.2 Medication Delivery 216
10.2.3 Renal 217
10.2.4
Products 218
10.2.5 History 219
10.3 Value Chain Analysis 221
10.3.1 Manufacturing 221
10.3.2 Product Development 222
10.3.3 Sales
and Marketing 222
10.4 SWOT Analysis 224
10.4.1 Baxter International
Inc. Strengths 224
10.4.2 Baxter International Inc. Weaknesses 225
10.4.3 Baxter International Inc. Opportunities 225
10.4.4 Baxter
International Inc. Threats 226
10.5 Revenue Analysis 227
10.5.1
Revenue by Segment 227
10.5.2 Revenue by Geography 228
10.6 Financial
and Operational Review 229
10.6.1 Financial Statements 229
10.6.2
Financial Ratios 230
10.7 Locations And Subsidiaries 231
10.8
Financial Deals Landscape 233
10.8.1 Baiyunshan And Baxter Form A Joint
Venture In China 233
10.8.2 Baxter Signs Licensing Agreement With
Intercytex And Spinal Restoration 234
10.8.3 Baxter Sells Transfusion
Therapies Business to Texas Pacific and Maverick Capital 236
10.8.4 B.
Braun Acquires Renal Therapy Business Of Baxter 238
10.8.5 Innovata signs
a license agreement with Baxter International 239
10.8.6 Kuros Biosurgery
Signs An Agreement With Baxter International 241
10.8.7 Gambro Signs An
Agreement With Baxter 242
10.8.8 Baxter Healthcare And Gambro Enter Into
An Agreement 244
10.8.9 Baxter and Cerus Enter Into Agreement With BioOne
for Commercialization Of INTERCEPT Blood System 245
10.8.10 Baxter
International And Kaketsuken Enter Into Agreement 247
10.8.11 Baxter To
Acquire 40% Stake In Shanghai Baxter From Worldbest Treeful 248
10.9
Recent Developments 250
10.9.1 Jan 24, 2008: Baxter Achieves Record Sales
and Earnings for Full-Year 2007 250
10.9.2 Dec 18, 2007: Baxter Elects CFO
252
10.9.3 Nov 13, 2007: Baxter Declares Quarterly Dividend 252
10.9.4
Aug 01, 2007: Baxter Elects New Board Director 252
10.9.5 Jul 31, 2007:
Baxter Announces Quarterly Dividend 253
10.9.6 Mar 13, 2007: Baxter
Declares Additional Share Repurchase Authorization 253
10.9.7 Feb 13,
2007: Baxter Announces Quarterly Dividend 253
10.9.8 Nov 28, 2006: Baxter
Announces Annual Dividend 254
10.9.9 Sep 14, 2006: Baxter Appoints
President, Baxter Latin America 254
10.10 Baxter International Inc.
Pipeline Products 255
10.10.1 Next-Generation Home Hemodialysis Machine
255
11 GlaxoSmithKline plc Company Profile 257
11.1 Company Overview
257
11.2 Business Overview 257
11.2.1 Products 258
11.2.2 History
258
11.3 Locations And Subsidiaries 261
11.4 Financial Deals Landscape
263
11.4.1 GlaxoSmithKline Acquires CNS 263
11.4.2 Bayer HealthCare
Acquires Pritor Business From GlaxoSmithKline 264
11.4.3 CNS To Merge
With GlaxoSmithKline 266
11.5 Recent Developments 268
11.5.1 Mar 19,
2008: GSK charitable support valued at GBP282 million in 2007 268
11.5.2
Feb 07, 2008: Full-year results announcement 2007 268
11.5.3 Dec 19, 2007:
GlaxoSmithKline And Santaris Enter Global R&D Alliance 268
11.5.4 Dec 10,
2007: GlaxoSmithKline And OncoMed Form Strategic Alliance To Develop Cancer
Stem Cell Antibody Therapeutics 269
11.5.5 Dec 07, 2007: GlaxoSmithKline
Announces Board And Management Changes 270
12 Novartis AG Company Profile
271
12.1 Company Overview 271
12.2 Business Overview 271
12.2.1
Major Products and Services 272
12.3 Locations And Subsidiaries 273
12.4 Financial Deals Landscape 275
12.4.1 Bayer Schering Pharma Acquires
U.S. Biologics Manufacturing Facility From Novartis 275
12.4.2 Novartis To
Acquire Majority Stake In Alcon From Nestle 276
12.4.3 Novartis to sell
Medical Nutrition business unit to Nestlé 278
12.4.4 Nestlé to Acquire
Novartis Medical Nutrition 280
12.4.5 Novartis to sell its division Gerber
Products Company to Nestle 281
13 Regulation System 284
13.1 Medical
Equipment Approval Process 284
13.1.1 Market Authorization Holder (MAH)
284
13.1.2 Classification and Pre-Market Approval of Medical Devices
285
13.1.3 Third Party Certification for Controlled Medical Devices
286
13.1.4 PMDA Approval for Highly Controlled Medical Devices 287
13.1.5 Registration Time 288
13.1.6 Registration Fee 288
13.1.7 Post
Marketing Surveillance 289
13.1.8 Labeling and Packaging 289
14
Pricing and Reimbursement 290
14.1 Market Pricing 290
14.2
Reimbursement Policies 290
14.3 Reimbursement Classes 291
14.3.1 Class
A 291
14.3.2 Class B 292
14.3.3 Class C 292
14.3.4 Class F 292
14.4 Request for Reimbursement 292
14.5 Reduction in Reimbursement for
Medical Devices and Drugs 292
15 Distribution Structure 293
16
APPENDIX 295
16.1 Global Markets Direct Research Methodology 295
16.2
Coverage 296
16.3 Secondary Research 296
16.4 Primary Research 297
16.5 Models 297
16.6 Forecasts 298
16.7 Expert Panels 298
16.8
Currency Conversion 299
16.9 Contact Us 300
16.10 Disclaimer 300
1.1 List of Tables
Table 1: Healthcare Expenditure in Japan,
2000 - 2005 19
Table 2: Number of Healthcare Institutions in Japan, 1995
-- 2004 21
Table 3: Number of Hospital Beds in Japan, 1995 -- 2004 21
Table 4: Number of Medical Personnel in Japan, 1995 - 2004 22
Table 5:
Number of Medical Care Institutions and Beds in Japan, 2000 - 2004 23
Table 6: Drug Delivery Devices, Japan, Overall Revenues ($ mn), 2000-2012
24
Table 7: Drug Delivery Devices, Japan, Overall Revenues ($ mn),
Historic, 2000-2007 25
Table 8: Drug Delivery Devices, Japan, Overall
Revenues ($ mn), Forecast, 2007-2012 26
Table 9: Drug Delivery Devices,
Japan, Category Revenues ($ mn), 2000-2012 27
Table 10: Drug Delivery
Devices, Japan, Category Revenues ($ mn), Historic, 2000-2007 28
Table 11:
Drug Delivery Devices, Japan, Category Revenues ($ mn), Forecast, 2007-2012
29
Table 12: Drug Delivery Devices, Japan, Category Volume (Units),
2000-2012 30
Table 13: Drug Delivery Devices, Japan, Category Volume
(Units), Historic, 2000-2007 31
Table 14: Drug Delivery Devices, Japan,
Category Volume (Units), Forecast, 2007-2012 32
Table 15: Drug Delivery
Devices, Japan, Company Share by Revenue ($ mn), 2005-2006 33
Table 16:
Inhalation Systems, Japan, Overall Revenues ($ mn), Historic, 2000-2007 34
Table 17: Inhalation Systems, Japan, Overall Revenues ($ mn), Forecast,
2007-2012 35
Table 18: Inhalation Systems, Japan, Revenue by Segment ($
mn), Historic, 2000-2007 36
Table 19: Inhalation Systems, Japan, Revenue
by Segment ($ mn), Forecast, 2007-2012 37
Table 20: Metered Dose Inhaler
Devices, Japan, Overall Revenues ($ mn), Historic, 2000-2007 38
Table 21:
Metered Dose Inhaler Devices, Japan, Overall Revenues ($ mn), Forecast,
2007-2012 39
Table 22: Dry Powder Inhaler Devices, Japan, Overall Revenues
($ mn), Historic, 2000-2007 40
Table 23: Dry Powder Inhaler Devices,
Japan, Overall Revenues ($ mn), Forecast, 2007-2012 41
Table 24:
Inhalation Systems, Japan, Overall Volume (Units), Historic, 2000-2007 42
Table 25: Inhalation Systems, Japan, Overall Volume (Units), Forecast,
2007-2012 43
Table 26: Metered Dose Inhaler Devices, Japan, Overall Volume
(Units), Historic, 2000-2007 44
Table 27: Metered Dose Inhaler Devices,
Japan, Overall Volume (Units), Forecast, 2007-2012 45
Table 28: Dry Powder
Inhaler Devices, Japan, Overall Volume (Units), Historic, 2000-2007 46
Table 29: Dry Powder Inhaler Devices, Japan, Overall Volume (Units), Forecast,
2007-2012 47
Table 30: Metered Dose Inhaler Devices, Japan, Average Price
($), Historic, 2000-2007 48
Table 31: Metered Dose Inhaler Devices, Japan,
Average Price ($), Forecast, 2007-2012 49
Table 32: Dry Powder Inhaler
Devices, Japan, Average Price ($), Historic, 2000-2007 50
Table 33: Dry
Powder Inhaler Devices, Japan, Average Price ($), Forecast, 2007-2012 51
Table 34: Inhalation Systems, Japan, Distribution Share by Revenue ($ mn),
2005-2006 52
Table 35: Inhalation Systems, Japan, Company Share by Revenue
($ mn), 2005-2006 53
Table 36: Infusion Systems, Japan, Overall Revenues
($ mn), Historic, 2000-2007 54
Table 37: Infusion Systems, Japan, Overall
Revenues ($ mn), Forecast, 2007-2012 55
Table 38: Infusion Systems, Japan,
Revenue by Segment ($ mn), Historic, 2000-2007 56
Table 39: Infusion
Systems, Japan, Revenue by Segment ($ mn), Forecast, 2007-2012 57
Table
40: Infusion Disposable Sets, Japan, Overall Revenues ($ mn), Historic,
2000-2007 58
Table 41: Infusion Disposable Sets, Japan, Overall Revenues
($ mn), Forecast, 2007-2012 59
Table 42: Syringe Pumps, Japan, Overall
Revenues ($ mn), Historic, 2000-2007 60
Table 43: Syringe Pumps, Japan,
Overall Revenues ($ mn), Forecast, 2007-2012 61
Table 44: Infusion Pumps,
Japan, Overall Revenues ($ mn), Historic, 2000-2007 62
Table 45: Infusion
Pumps, Japan, Overall Revenues ($ mn), Forecast, 2007-2012 63
Table 46:
Infusion Systems, Japan, Overall Volume (Units), Historic, 2000-2007 64
Table 47: Infusion Systems, Japan, Overall Volume (Units), Forecast, 2007-2012
64
Table 48: Infusion Disposable Sets, Japan, Overall Volume (Units),
Historic, 2000-2007 65
Table 49: Infusion Disposable Sets, Japan, Overall
Volume (Units), Forecast, 2007-2012 66
Table 50: Syringe Pumps, Japan,
Overall Volume (Units), Historic, 2000-2007 67
Table 51: Syringe Pumps,
Japan, Overall Volume (Units), Forecast, 2007-2012 68
Table 52: Infusion
Pumps, Japan, Overall Volume (Units), Historic, 2000-2007 69
Table 53:
Infusion Pumps, Japan, Overall Volume (Units), Forecast, 2007-2012 70
Table 54: Infusion Pumps, Japan, Average Price ($), Historic, 2000-2007 71
Table 55: Infusion Pumps, Japan, Average Price ($), Forecast, 2007-2012 72
Table 56: Syringe Pumps, Japan, Average Price ($), Historic, 2000-2007 73
Table 57: Syringe Pumps, Japan, Average Price ($), Forecast, 2007-2012 74
Table 58: Infusion Disposable Sets, Japan, Average Price ($), Historic,
2000-2007 75
Table 59: Infusion Disposable Sets, Japan, Average Price ($),
Forecast, 2007-2012 76
Table 60: Infusion Systems, Japan, Distribution
Share by Revenue ($ mn), 2005-2006 77
Table 61: Infusion Systems, Japan,
Company Share by Revenue ($ mn), 2005-2006 78
Table 62: Needle Free
Injections, Japan, Overall Revenues ($ mn), Historic, 2000-2007 79
Table
63: Needle Free Injections, Japan, Overall Revenues ($ mn), Forecast,
2007-2012 80
Table 64: Needle Free Injections, Japan, Overall Volume
(Units), Historic, 2000-2007 81
Table 65: Needle Free Injections, Japan,
Overall Volume (Units), Forecast, 2007-2012 82
Table 66: Needle Free
Injections, Japan, Average Price ($), Historic, 2000-2007 83
Table 67:
Needle Free Injections, Japan, Average Price ($), Forecast, 2007-2012 84
Table 68: Needle Free Injections, Japan, Distribution Share by Revenue ($ mn),
2005-2006 85
Table 69: Needle Free Injections, Japan, Company Share by
Revenue ($ mn), 2005-2006 86
Table 70: AstraZeneca PLC, Subsidiaries
92
Table 71: 3M Company, SWOT Analysis, 2006 143
Table 72:
3M Company, Revenue by Segment, USD Million, 2003-2007 147
Table 73:
3M Company, Revenue by Geography, USD Million, 2003-2007 148
Table 74:
3M Company, Financial Statements, USD Million, 2003-2007 149
Table 75:
3M Company, Financial Ratios, USD Million, 2003-2007 150
Table 76:
3M Company, Subsidiaries 151
Table 77: Baxter International Inc.,
SWOT Analysis, 2006 224
Table 78: Baxter International Inc., Revenue
by Segment, USD Million, 2003-2007 227
Table 79: Baxter International
Inc., Revenue by Geography, USD Million, 2003-2007 228
Table 80:
Baxter International Inc., Financial Statements, USD Million, 2003-2007
229
Table 81: Baxter International Inc., Financial Ratios, USD
Million, 2003-2007 230
Table 82: Baxter International Inc., Other
Locations 231
Table 83: Baxter International Inc., Subsidiaries
232
Table 84: GlaxoSmithKline plc, Subsidiaries 261
Table 84:
GlaxoSmithKline plc, Subsidiaries(Contd..) 262
Table 85: Novartis
Medical Nutrition, Other Locations 273
Table 85: Novartis Medical
Nutrition, Other Locations(Contd..) 274
Table 86: Registration Processing
Time for Medical Devices in Japan, 2007 288
Table 87: Product Registration
Fee for Medical Devices in Japan, 2007 288
Table 88: Currency Conversion
from USD to Local Currency at 2007 Constant Rate 299
1.2 List of
Figures
Figure 1: Healthcare Expenditure in Japan, 2000 -- 2005 19
Figure 2: Government and Private Healthcare Expenditure in Japan, 2005 20
Figure 3: Drug Delivery Devices, Japan, Overall Revenues ($ mn), 2000-2012
24
Figure 4: Drug Delivery Devices, Japan, Overall Revenues ($ mn),
Historic, 2000-2007 25
Figure 5: Drug Delivery Devices, Japan, Overall
Revenues ($ mn), Forecast, 2007-2012 26
Figure 6: Drug Delivery Devices,
Japan, Category Revenues ($ mn), 2000-2012 27
Figure 7: Drug Delivery
Devices, Japan, Category Revenues ($ mn), Historic, 2000-2007 28
Figure 8:
Drug Delivery Devices, Japan, Category Revenues ($ mn), Forecast, 2007-2012
29
Figure 9: Drug Delivery Devices, Japan, Category Volume (Units),
2000-2012 30
Figure 10: Drug Delivery Devices, Japan, Category Volume
(Units), Historic, 2000-2007 31
Figure 11: Drug Delivery Devices, Japan,
Category Volume (Units), Forecast, 2007-2012 32
Figure 12: Drug Delivery
Devices, Japan, Company Share (%), 2006 33
Figure 13: Inhalation Systems,
Japan, Overall Revenues ($ mn), Historic, 2000-2007 34
Figure 14:
Inhalation Systems, Japan, Overall Revenues ($ mn), Forecast, 2007-2012 35
Figure 15: Inhalation Systems, Japan, Revenue by Segment ($ mn), Historic,
2000-2007 36
Figure 16: Inhalation Systems, Japan, Revenue by Segment ($
mn), Forecast, 2007-2012 37
Figure 17: Metered Dose Inhaler Devices,
Japan, Overall Revenues ($ mn), Historic, 2000-2007 38
Figure 18: Metered
Dose Inhaler Devices, Japan, Overall Revenues ($ mn), Forecast, 2007-2012
39
Figure 19: Dry Powder Inhaler Devices, Japan, Overall Revenues ($ mn),
Historic, 2000-2007 40
Figure 20: Dry Powder Inhaler Devices, Japan,
Overall Revenues ($ mn), Forecast, 2007-2012 41
Figure 21: Inhalation
Systems, Japan, Overall Volume (Units), Historic, 2000-2007 42
Figure 22:
Inhalation Systems, Japan, Overall Volume (Units), Forecast, 2007-2012 43
Figure 23: Metered Dose Inhaler Devices, Japan, Overall Volume (Units),
Historic, 2000-2007 44
Figure 24: Metered Dose Inhaler Devices, Japan,
Overall Volume (Units), Forecast, 2007-2012 45
Figure 25: Dry Powder
Inhaler Devices, Japan, Overall Volume (Units), Historic, 2000-2007 46
Figure 26: Dry Powder Inhaler Devices, Japan, Overall Volume (Units),
Forecast, 2007-2012 47
Figure 27: Metered Dose Inhaler Devices, Japan,
Average Price ($), Historic, 2000-2007 48
Figure 28: Metered Dose Inhaler
Devices, Japan, Average Price ($), Forecast, 2007-2012 49
Figure 29: Dry
Powder Inhaler Devices, Japan, Average Price ($), Historic, 2000-2007 50
Figure 30: Dry Powder Inhaler Devices, Japan, Average Price ($), Forecast,
2007-2012 51
Figure 31: Inhalation Systems, Japan, Distribution Share (%),
2006 52
Figure 32: Inhalation Systems, Japan, Company Share (%), 2006
53
Figure 33: Infusion Systems, Japan, Overall Revenues ($ mn), Historic,
2000-2007 54
Figure 34: Infusion Systems, Japan, Overall Revenues ($ mn),
Forecast, 2007-2012 55
Figure 35: Infusion Systems, Japan, Revenue by
Segment ($ mn), Historic, 2000-2007 56
Figure 36: Infusion Systems, Japan,
Revenue by Segment ($ mn), Forecast, 2007-2012 57
Figure 37: Infusion
Disposable Sets, Japan, Overall Revenues ($ mn), Historic, 2000-2007 58
Figure 38: Infusion Disposable Sets, Japan, Overall Revenues ($ mn), Forecast,
2007-2012 59
Figure 39: Syringe Pumps, Japan, Overall Revenues ($ mn),
Historic, 2000-2007 60
Figure 40: Syringe Pumps, Japan, Overall Revenues
($ mn), Forecast, 2007-2012 61
Figure 41: Infusion Pumps, Japan, Overall
Revenues ($ mn), Historic, 2000-2007 62
Figure 42: Infusion Pumps, Japan,
Overall Revenues ($ mn), Forecast, 2007-2012 63
Figure 43: Infusion
Disposable Sets, Japan, Overall Volume (Units), Historic, 2000-2007 65
Figure 44: Infusion Disposable Sets, Japan, Overall Volume (Units), Forecast,
2007-2012 66
Figure 45: Syringe Pumps, Japan, Overall Volume (Units),
Historic, 2000-2007 67
Figure 46: Syringe Pumps, Japan, Overall Volume
(Units), Forecast, 2007-2012 68
Figure 47: Infusion Pumps, Japan, Overall
Volume (Units), Historic, 2000-2007 69
Figure 48: Infusion Pumps, Japan,
Overall Volume (Units), Forecast, 2007-2012 70
Figure 49: Infusion Pumps,
Japan, Average Price ($), Historic, 2000-2007 71
Figure 50: Infusion
Pumps, Japan, Average Price ($), Forecast, 2007-2012 72
Figure 51: Syringe
Pumps, Japan, Average Price ($), Historic, 2000-2007 73
Figure 52: Syringe
Pumps, Japan, Average Price ($), Forecast, 2007-2012 74
Figure 53:
Infusion Disposable Sets, Japan, Average Price ($), Historic, 2000-2007 75
Figure 54: Infusion Disposable Sets, Japan, Average Price ($), Forecast,
2007-2012 76
Figure 55: Infusion Systems, Japan, Distribution Share (%),
2006 77
Figure 56: Infusion Systems, Japan, Company Share (%), 2006 78
Figure 57: Needle Free Injections, Japan, Overall Revenues ($ mn), Historic,
2000-2007 79
Figure 58: Needle Free Injections, Japan, Overall Revenues ($
mn), Forecast, 2007-2012 80
Figure 59: Needle Free Injections, Japan,
Overall Volume (Units), Historic, 2000-2007 81
Figure 60: Needle Free
Injections, Japan, Overall Volume (Units), Forecast, 2007-2012 82
Figure
61: Needle Free Injections, Japan, Average Price ($), Historic, 2000-2007
83
Figure 62: Needle Free Injections, Japan, Average Price ($), Forecast,
2007-2012 84
Figure 63: Needle Free Injections, Japan, Distribution Share
(%), 2006 85
Figure 64: 3M Company, Value Chain Analysis 140
Figure 65: Baxter International Inc., Value Chain Analysis 221
Figure
66: Medical Device Classification in Japan, 2007 285
Figure 67: Approval
Process for Controlled Medical Devices in Japan, 2007 286
Figure 68:
Approval Process for Highly Controlled Medical Devices in Japan, 2007 287
Figure 69: Health Insurance Reimbursement Process in Japan, 2007 291
Figure 70: Distribution Structure for Medical Equipment in Japan, 2007 294
Figure 71: Global Markets Direct Methodology 295
